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Introduction  and  Objectives: The  role  of  endothelial  dysfunction  (ED)  in  patients  with  ST-
elevation myocardial  infarction  (STEMI)  is poorly  understood.  Peripheral  arterial  tonometry
(PAT)  allows  non-invasive  evaluation  of  ED,  but  has  never  been  used  for  this purpose  early  after
primary percutaneous  coronary  intervention  (P-PCI).  Our  purpose  was  to  analyze  the  relation
between ED  assessed  by  PAT  and both  the  presence  of  microvascular  obstruction  (MVO)  and
infarct extension  in  STEMI  patients.
Methods:  ED  was  assessed  by  the  reactive  hyperemia  index  (RHI),  measured  by  PAT  and  defined
as RHI  <1.67.  Infarct  extension  was  assessed  by  troponin  I (TnI)  release  and  contrast-enhanced
cardiac  magnetic  resonance  (ceCMR).  MVO  was  assessed  by  ceCMR  and  by  indirect  angiographic
and ECG  indicators.  An  echocardiogram  was  also  performed  in the  first  12  h.
Results:  We  included  38  patients  (mean  age  60.0±13.7  years,  29  male).  Mean  RHI  was  1.87±0.60
and 16  patients  (42.1%)  had  ED.  Peak  TnI  (median  118  mg/dl,  IQR  186  vs.  67/81,  p=0.024)  and
AUC of TnI  (median  2305,  IQR  2486  vs.  1076/1042,  p=0.012)  were  significantly  higher  in patients
with ED,  who  also  showed  a  trend  for  more  transmural  infarcts  (63.6%  vs.  22.2%,  p=0.06)  and
larger infarct  mass  on  ceCMR  (median  17.5%,  IQR  15.4  vs.  10.1/10.3,  p=0.08).  Left  ventricular
ejection fraction  (LVEF)  was  lower  and  wall  motion  score  index  (WMSI)  was  higher  on  both
echocardiogram  and  ceCMR  in  patients  with  ED.  On  ceCMR,  MVO  was  more  frequent  in patients
with RHI  <1.67  (54.5%  vs.  11.1%,  p=0.03).  ECG  and  angiographic  indicators  of  MVO  all  showed  a
trend toward  worse  results  in these  patients.
Conclusions:  The  presence  of  ED assessed  by  PAT  24  h after  P-PCI  in  patients  with  STEMI  is
associated with  larger  infarcts,  lower  LVEF,  higher  WMSI  and  higher  prevalence  of  MVO.
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Índice  de  hiperemia
reativa
A disfunção  endotelial  precoce  prevê  a extensão  do  enfarte  e  a presença
de  obstrução microvascular  em  doentes  com  enfarte  agudo  do  miocárdio
Resumo
Introdução  e objetivos:  O  papel  da  disfunção  endotelial  (DE)  em  doentes  com  enfarte  agudo  do
miocárdio  com  elevação do  segmento  ST (EAMcST)  é mal  compreendido.  A  tonometria  arterial
periférica (TAP)  permite  avaliar  de forma  não  invasiva  a  DE,  mas  nunca  foi usada  precocemente
após intervenção coronária  percutânea  primária  (ICP-P).  O  nosso  objetivo  foi avaliar  a  relação
entre a  DE  avaliada  por  TAP,  a  presença de obstrução microvascular  (OMV)  e a  extensão  do
enfarte (EE)  em  doentes  com  EAMcST.
Métodos:  A DE  foi  avaliada  pelo  índice  de hiperemia  reativa  (IHR),  obtido  por  TAP,  sendo
definida como  um valor  de IHR  <1,67.  A  EE  foi  avaliada  pela  troponina  I  (TnI)  e por  ressonância
magnética  cardíaca  com  contraste  (RMCc).  A OMV  foi  avaliada  por  RMCc  e  por  indicadores  indi-
retos eletrocardiográficos  e angiográficos.  Foi  ainda  efetuado  um  ecocardiograma  nas primeiras
12 horas.
Resultados:  Foram  incluídos  38  doentes  (idade  média  60,0±13,7  anos,  29  homens).  Os  valores
médios de  IHR  foram  1,87±0,60  e  16  doentes  (42,1%)  tinham  DE.  Os  valores  máximos  (mediana
118/IIQ 186  versus  67/81,  p=0,024)  e a  área  sob  a  curva  de TnI  (mediana  2305/IIQ  2486  versus
1076/1042,  p=0,012)  foram  significativamente  superiores  nos  doentes  com  DE,  que  também
mostraram  uma  tendência  para  mais  enfartes  transmurais  (63,6  versus  22,2%,  p=0,06)  e  maiores
massas de  enfarte  na  RMCc  (mediana  17,5/IIQ  15,4  versus  10,1/10,3,  p=0,08).  Os doentes  com
DE mostraram  valores  de  fração de ejeção do  ventrículo  esquerdo  (FEVE)  significativamente
menores e valores  do índice  de  motilidade  segmentar  (IMS)  significativamente  maiores,  por
ecocardiografia  e por  RMCc.  A  presença  de  OMV na  RMCc  foi mais  frequente  nos  doentes  com
DE (54,5  versus  11,1%,  p=0,03).
Conclusões:  A  presença  de DE  avaliada  por  TAP  24  horas  após  ICP-P,  em  doentes  com  EAMcST,
associa-se  a  enfartes  maiores,  menor  FEVE,  maior  IMS  e maior  prevalência  de OMV.
© 2017  Sociedade  Portuguesa  de Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos  os
direitos reservados.
Introduction
Notwithstanding  all  the improvements  seen  in primary
angioplasty  programs,  with  dramatic  reductions  in the time
between  symptom  onset  and  intervention,  and  although
normal  epicardial  coronary  artery  flow  is almost  always
achieved  in  a  timely  fashion  after  primary  percutaneous
coronary  intervention  (P-PCI)  in patients  with  ST-elevation
myocardial  infarction  (STEMI),  a  significant  proportion  of
patients  (between  20%  and  60%) have a poor  outcome
because  of  microvascular  coronary  damage.1,2
The  negative  prognostic  implications  for  the  risk  of
left  ventricular  (LV)  remodeling  and  of  hard  endpoints,
including  death,  associated  with  coronary  microvascular
damage  have  been  repeatedly  confirmed  with  several  inva-
sive  and  non-invasive  indicators.2--13 However,  the precise
mechanisms  underlying  coronary  microcirculatory  dysfunc-
tion  before  and  after the restoration  of  epicardial  blood
flow  are  largely  unknown  and  likely  to be  multifactorial.
Traditionally,  coronary  microvascular  dysfunction  in this set-
ting  is  seen  as  a  consequence  of  the primary  epicardial
event  and/or  of  coronary  reperfusion,  either  pharmaco-
logical  (thrombolysis)  or  mechanical  (P-PCI).  Mechanical
obstruction  (due to  distal  embolization  of  atherothrombotic
debris14),  coronary  endothelial  dysfunction  (ED)  (mediated
by  the  release  of  vasoactive  factors  such as  endothelin-1
and tissue  factor15) and  reperfusion  injury  (through  various
mechanisms  including  platelet  and leukocyte  accumulation
leading  to  thrombosis,  vasoconstriction  and release  of free
oxygen  radicals,  proteases,  and  pro-inflammatory  media-
tors,  and  complement  activation  leading  to  the release  of
histamine  and  to  increased  cell  permeability,  resulting  in
endothelial  cell  and  myocyte  swelling,  interstitial  edema,
and  further  stimulation  of  leukocyte  adherence16), have
all  been  suggested  as mechanisms  involved  in  coronary
microvascular  dysfunction  in  STEMI  patients.
An  alternative  explanation  is  that  pre-existing  and/or
simultaneous  coronary  microvascular  dysfunction  may  itself
have  pathophysiological  importance  and  contribute  to
myocardial  infarct  extension,  LV  remodeling  and  future
events.16 Whichever  theory  of microvascular  coronary  dys-
function  in STEMI  patients  is  correct  (cause,  consequence
or  both), endothelial  function  always  seems  to  be  at the
core  of  the proposed  mechanisms.  There  is  accumulating
evidence  that  ED  is not  simply  a  risk  factor  and  precur-
sor  of coronary  artery  disease  (CAD),  but  also  plays  a
central  role  in processes  leading  to  acute  coronary  syn-
drome  (ACS)  and STEMI.17 In patients  with  ACS,  endothelial
function,  measured  in the peripheral  circulation,  has been
shown  to  be an independent  predictor  of events,18 and
subsequent  normalization  of  endothelial  function  in these
patients  predicts  a lower  risk.19,20 Similarly,  in  STEMI
The  endothelial  dysfunction  in patients  with  ST-elevation  myocardial  infarction  733
List  of  abbreviations
ACS  acute  coronary  syndrome
APPROACH  Alberta Provincial  Project  for  Outcome
Assessment  in  Coronary  Heart  Disease
AUC  area  under  the curve
BARI  Bypass  Angioplasty  Revascularization  Investi-
gation
CAD  coronary  artery  disease
ceCMR  contrast-enhanced  cardiac  magnetic  reso-
nance
CRT  cardiac  resynchronization  therapy
cTFC  corrected  TIMI  frame  count
ED  endothelial  dysfunction
GLS  global  longitudinal  strain
IQR  interquartile  range
LV  left  ventricular
LVEF  left  ventricular  ejection  fraction
IMR  index  of  microcirculatory  resistance
MVO  microvascular  obstruction
NO  nitric  oxide
NSTE-ACS  non-ST  elevation  acute  coronary  syndrome
P-PCI  primary  percutaneous  coronary  intervention
PAT  peripheral  arterial  tonometry
RHI  reactive  hyperemia  index
STEMI  ST-elevation  myocardial  infarction
TMPG  TIMI  myocardial  perfusion  grade
TnI  troponin  I
WMSI  wall  motion  score  index
patients  treated  with  P-PCI,  peripheral  ED  was  associ-
ated  with  larger  infarctions  as  measured  by peak  troponin
levels,21 and  endothelial  function improvement  six months
after  the  event  also  correlated  with  lower  end-diastolic  LV
volumes.22
It is  therefore  plausible  to speculate  that  previous  ED
or  a  blunted  reaction  of  endothelial  mechanisms  during
STEMI  may  be  a central  component  of  coronary  microvas-
cular  dysfunction  in  these  patients  and,  as  a consequence,  a
determinant  of  microvascular  reperfusion,  infarction  exten-
sion  and  LV  remodeling.  Ideally,  this hypothesis  would
best  be  proved  if endothelial  function  had  been  assessed
before  the  myocardial  infarction,  which  clearly  is  not  pos-
sible.  In fact,  most  studies  assessing  endothelial  function
in  ACS  patients  were  performed  relatively  late  (several
days  or  weeks)  after  the  onset  of  the event.21,23--27 Con-
sequently,  the  worse  results  documented  in patients  with
ED  may  simply  be  a  consequence  of  larger and more  com-
plicated  infarcts.  Taking  peripheral  endothelial  function
(which  is much  easier  to  measure)  as  a  surrogate  of  coro-
nary  endothelial  function,  if the above  theory  were true  we
would  expect  worse  acute  ED, worse  microvascular  reper-
fusion  and  worse  LV  remodeling  in  patients  with  larger
infarcts.
The  purpose  of this pilot  study  was  to  analyze  the  relation
between  peripheral  endothelial  function  assessed  early  (24  h
after  reperfusion)  by  peripheral  arterial  tonometry  (PAT),
the  presence  of microvascular  obstruction  (MVO)  and  the
extent  of myocardial  infarction.
Methods
Patients  admitted  with  a first STEMI  and  treated  with  P-PCI
were  prospectively  included.  The  inclusion  criteria  were
chest  pain  lasting  at least  20  min and ST-segment  eleva-
tion  of  at least  1 mm in  two  or  more  contiguous  leads;
pain-to-balloon  time  less  than  6 h  (or 6-12  h  if ongoing
pain);  P-PCI  performed  successfully  on  the culprit  lesion  in
a  native  coronary  artery;  age  over 18  years;  and  informed
consent  obtained.  Exclusion  criteria  were  previous  history  of
myocardial  infarction;  left bundle  branch  block;  implanted
pacemaker;  cardiogenic  shock; known  myocardial  disease
and  severe  LV hypertrophy  (>15  mm);  previous  coronary
artery  bypass  surgery;  percutaneous  revascularization  in
the  previous  three  months;  contraindication  to  adenosine;
and  any  serious  non-cardiac  disease  associated  with  a life
expectancy  of  less  than  12  months.  The  institutional  ethics
committee  approved  the  study,  which  was  conducted  in
compliance  with  the  Declaration  of  Helsinki.
P-PCI  and  adjuvant  treatment  were  performed  according
to  standard  of  care  for  patients  with  acute  STEMI.  Endothe-
lial  function  was assessed  24  h  after  P-PCI  by  PAT.  Infarct
extension  was  assessed  by  contrast-enhanced  cardiac  mag-
netic  resonance  (ceCMR)  and by  the  release  of  troponin  I.
MVO  was  assessed  by  ceCMR  and also  by  indirect  indica-
tors,  including  ST resolution  on  the  electrocardiogram  (ECG)
and  angiographic  indicators  (corrected  TIMI  frame  count
[cTFC],  TIMI  myocardial  perfusion  grade  [TMPG]  and  index  of
microcirculatory  resistance  [IMR]).  Additionally,  an echocar-
diographic  exam  was  performed  in the  first  12  h  after  P-PCI.
Assessment  of endothelial  function  --  peripheral
arterial  tonometry
Endothelial  function  was  assessed  by  PAT, using  EndoPAT  2000
(Itamar  Medical
®
, Caesarea,  Israel).  The  protocol  was  the
same  as  followed  in previous  studies.28 Briefly,  a complete
digital  PAT endothelial  function  test  includes  three  phases:
baseline,  occlusion,  and  hyperemia.  A blood  pressure  cuff  is
placed  on  one  upper  arm  (study  arm),  while  the other  arm
serves  as  a control  (control  arm).  A PAT  probe  is  positioned
on  one  finger  of  each  hand and set  by  the computer  to  inflate
to  10  mmHg  below diastolic  pressure  or  70  mmHg  (the  lower
value  is  selected).  Recordings  are  taken  simultaneously  from
both  fingers  throughout  the  study.  The  response  in the  con-
trol  finger  not experiencing  hyperemia  can be used  to  adjust
for  systemic  effects.  After  baseline  data  acquisition,  the
blood  pressure  cuff is  inflated  on  one  arm  to  suprasystolic
pressures  for  5 min.  During the occlusion  period,  signals  are
absent  from  the hyperemic  finger  but  continue  from  the con-
trol  finger.  Following  cuff release,  pulse  amplitude  increases
in  the  hyperemic  finger.  The  pulse  amplitude  recordings  are
digitized  and  analyzed  by  an  automated,  proprietary  algo-
rithm.  Average  pulse  amplitude  is calculated  for  each  30-s
interval  following  cuff  occlusion  for  up  to 5  min.  As  a  mea-
sure  of reactive  hyperemia,  the  reactive  hyperemia  index
(RHI)  is  then  calculated  as  the ratio  of  the average  ampli-
tude  of  the  PAT signal  over  a  1-min time  interval  starting
1 min  after  cuff deflation  divided  by  the average  ampli-
tude  of  the  PAT signal  of  a 3.5-min  time  period  before  cuff
inflation  (baseline).  Subsequently,  PAT index  values  from  the
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study  arm  are normalized  to  the control  arm.  These  data  are
analyzed  by a computer  in an operator-independent  manner.
ED  was  defined  as  RHI <1.67,  as  previously  described.28
Contrast-enhanced  cardiac  magnetic  resonance
Cardiac  magnetic  resonance  was  performed  in a subset  of
patients  on  the 7th-8th  day post-MI,29 using  a 1.5-T  mag-
netic  resonance  imaging  system  (Avanto,  Siemens  Medical
Systems,  Erlangen,  Germany)  equipped  with  a  dedicated
cardiac  software  package  and  eight  available  independent
radiofrequency  receiver  channels,  cardiac  coil,  and  vec-
torcardiogram.  After acquisition  of  localizing  images,  long-
and  short-axis  cine  images  were obtained,  using  retrospec-
tively  ECG-gated  breath-hold  segmented  K-space  balanced
steady-state  free  precession  pulse  sequences  (trueFISP).
The  short-axis  cine scans  of  6-mm slices  were used  to
determine  LV  mass,  volume,  and function  (in-plane  reso-
lution  1.6  mm×1.6 mm;  gap  2 mm).  A  short  tau  inversion
recovery  (STIR)  technique,  with  triple inversion  recovery
black-blood  turbo-spin  echo  pulse  sequences,  was  used
to  quantify  edema  (area at  risk). A  bolus  of contrast
medium  (gadopentetate  dimeglumine:  Magnevist,  Schering
AG,  Berlin,  Germany)  was  injected  at a  dose  of 0.2  mmol/kg.
Early  enhancement  images  for  assessment  of  MVO  were
obtained  by  acquiring  an  inversion-recovery  segmented  gra-
dient  echo  T1-weighted  sequence  with  a  high  inversion  time
(approximately  500 ms)  2-4  min  after  gadolinium  injec-
tion.  Delayed  enhancement  images  were then  obtained  by
acquiring  an inversion-recovery  segmented  gradient  echo
T1-weighted  sequence,  10-15  min after  the bolus. All  post-
processing  and  analyses  of  the area  at risk,  myocardial
infarct  size,  and  presence  of  MVO  were performed  using
cvi42 version  5 software  (Circle  Cardiovascular  Imaging  Inc,
Calgary,  Canada)  by  a  cardiologist  experienced  in cardiac
magnetic  resonance  and  blinded  to  all  clinical  and  inva-
sive  physiological  data.  The  area at risk  was  manually
quantified  on  short-axis  STIR  sequence  slices,  delineating
higher  intensity  areas  (no  threshold  definition)  on  each  slice,
and  infarct  mass  was  subsequently  computed.  Infarct  size
was  also  assessed  manually  by  planimetry  on  each  short-
axis  slice,  delineating  the hyperenhanced  area,  including
areas  of  hypoenhancement  surrounded  by  the  hyperen-
hanced  area,  the latter  being  considered  MVO.  Infarct  size,
as  a  percentage  of  LV  mass,  was  computed  from  the sum
of  hyperenhanced  pixels  from  each  of the  10  short-axis
images  divided  by  the  total  number  of  pixels  within  the LV
myocardium  multiplied  by  100.30 MVO  mass  was  also  manu-
ally  quantified  as  the sum  of  hypoenhanced  pixels  on  delayed
enhancement  sequences  as  better  spatial  resolution  was
found  than  for  early  enhancement  sequences.31
Cardiac  biomarkers
Troponin  I (TnI)  values  were  used  to  quantify  myocardial
infarct  extent.  To  this  end,  blood  tests  were  collected  at
admission,  every  6 h  for  the first  24  h  (i.e. at 0, 6, 12,
18,  and  24  h), and  every  12  h  thereafter  until  48  h after
admission  (i.e.  at 36  and 48  h). TnI  was  measured  by  LOCITM
sandwich  chemiluminescent  immunoassay  with  a Dimen-
sion  VistaTM Intelligent  Lab  System  (Siemens  Healthcare
Diagnostics).  Peak  TnI  values  and  the  area  under  the
curve  (AUC)  of TnI  release  were  calculated,  as  previously
described.32 In order  to  account  for  lesion  location,  these
values  (AUC  of TnI  and  peak  TnI)  were  indexed  to area at risk
using  the Bypass  Angioplasty  Revascularization  Investigation
(BARI)  and  modified  Alberta  Provincial  Project  for  Outcome
Assessment  in Coronary  Heart  Disease  (APPROACH)  scores.33
Angiographic  indicators  of microvascular
obstruction
At  the  end  of  the P-PCI  procedure,  a  final  run  of  images  of  the
culprit  artery  was  recorded  at 30  frames  per  second  (fps),
in order  to measure  TIMI  frame  count  and  TIMI  perfusion
grade.  If necessary,  the view  was  adjusted  so  that  the cul-
prit  vessel  territory  was  not  superimposed.  Cine  filming  was
prolonged  for  at least three  cardiac  cycles,  to  ensure  that
the entire  washout  phase  was  included.  These  two  measures
of  flow  were  analyzed  offline  by  an  operator  blinded  to  other
assessments  of  that  patient.
cTFC  was  measured  as  the number  of  frames  required  for
epicardial  contrast to  reach  standardized  distal  landmarks,
as  previously  described.34 The  first  frame  used for  TIMI frame
counting  was  defined  as  the frame  in which  a column  of dye
touched  both  borders  of  the  coronary  artery  and  moved  for-
ward,  and the last  frame  was  defined  as  the frame  in  which
dye  began  to  enter  (but  not  necessarily  fill) a  standard  distal
landmark  in the artery.  These  frame  counts  were  corrected
for  the longer  length  of  the  left anterior  descending  coro-
nary  artery by  dividing  the frame  count  by 1.7, to  arrive  at
the cTFC.
TMPG  was  classified  according  to the standard
definition,35 in  which grade  3  corresponds  to  normal
entry  and exit  of  dye  from  the  microvasculature  (with  a
ground-glass  appearance  -- ‘blush’  --  or  opacification  of
the  myocardium  in the  distribution  of  the culprit  lesion
that  clears  normally,  and  is  either  gone  or  mildly  or  mod-
erately  persistent  at the  end  of  the  washout  phase),  and
grade  0  corresponds  to  the failure  of the dye  to enter  the
microvasculature.
IMR was  measured  immediately  after P-PCI,  as  previously
described.36,37 A 0.014′′ coronary  pressure  wire  (Certus,  St.
Jude  Medical)  was  calibrated  outside  the body,  equalized
to  the pressure  reading  from  the guide  catheter  with  the
pressure  sensor  positioned  at the ostium  of  the guiding
catheter  (after  intracoronary  administration  of  1-2  ml of
nitroglycerin),  and  then  advanced  to the distal  two-thirds
of  the  culprit vessel.  Maximal  hyperemia  was  induced  using
intravenous  adenosine  (140  g/kg/min)  via  a central  venous
catheter.  Approximately  3  ml of  room-temperature  saline
was  injected  down  the  culprit  vessel,  and  the hyperemic
transit  times  were  recorded  and  automatically  averaged,
using  the  RadiAnalyzerTM Xpress  console  (St.  Jude  Medical).
Mean  distal  coronary  pressures  were  recorded  during  peak
hyperemia.  IMR was  calculated  by  multiplying  the mean  dis-
tal  coronary  pressure  by the  mean  hyperemic  transit  time.
Echocardiographic  assessment
An  echocardiogram  was  performed  in  the first  12  h, by
an  operator  blinded  to  the EndoPAT,  ECG and  angiographic
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results,  using  a commercially  available  ultrasound  system
(Vivid  7,  GE  Healthcare).  Measurements  were  performed
offline  with  EchoPAC  version  113  (GE  Healthcare)  by  two
observers.  Parameters  were  measured  several  times  and
then  averaged.  Echocardiographic  quantification  of LVEF
was  determined  from  4- and  2-chamber  views  using  semi-
automatic  border  detection  based  on  feature  tracking
imaging.38 LV  regional  wall  motion  analysis  was  performed
and  the  wall  motion  score  index  (WMSI)  was  calculated  by
two-dimensional  (2D)  echocardiography,  according  to  the
European  Society  of  Echocardiography  recommendations,
using  the  17-segment  model on  a  scale  of  1  to  5: 1 normal,
2  hypokinesia,  3 akinesia,  4 dyskinesia,  5 aneurysmal.39
Mitral  inflow  was obtained  by  pulsed  wave  Doppler  echocar-
diography  with  the sample  volume  between  the mitral
leaflet  tips  during  diastole,  and  mitral  annulus  velocities
were  obtained  from  the average  of  the septal  and  lateral
annulus  by  tissue  Doppler  imaging.  The  ratio  of  early  dias-
tolic  mitral  inflow  velocity  to early  diastolic  mitral  annular
velocity  (E/e′)  was  calculated.  Left  atrial  volumes  were
obtained  by  2D  echocardiography  and indexed  to  body  sur-
face  area.  Global  LV  longitudinal  strain  (GLS)  was  assessed
using  speckle-tracking  analysis  with  automated  function
imaging.  Peak  longitudinal  strain  was  defined  as  the  change
in  length  of  the  myocardium  from  end-diastole  to  end-
systole  and  expressed  as  a percentage:  longitudinal  strain
(%)  = (L  end-systole  - L end-diastole)/L  end-diastole  ×  100,
where  L  is  the  length  of  the  region  of  interest.  GLS  was
obtained  from  2D  grayscale  images of  apical  4-chamber,
2-chamber,  and  long-axis  views with  optimized  frame  rate
(50-90  fps).  Software  identified  the endocardial  border,  and
myocardial  motion  was  automatically  tracked  in  each  imag-
ing  view.  In  segments  with  poor  tracking,  the observer
readjusted  the  endocardial  trace line  until  better  tracking
was  achieved.  The  mean  of the peak  systolic  longitudinal
strain  values  from  the 17  LV  segments  was  calculated  to
determine  LV  GLS.
Statistical  analysis
Continuous  variables  are presented  as  mean  ±  stan-
dard  deviation  (normal  distribution)  or  as  median  and
interquartile  range  (IQR)  (non-normal  distribution);  cate-
gorical  variables  are  presented  as  frequencies.  All  analyses
of  ED  (i.e.  RHI  <1.67  vs.  ≥1.67)  were  performed  using the
independent-sample  t  test  for  continuous  variables  with  a
normal  distribution,  the Mann-Whitney  test  for  continuous
variables  with  a  non-normal  distribution,  and  the chi-square
test  for  categorical  variables  (with  Fisher’s  correction  when
applicable).  Analysis  of  RHI as a  continuous  variable  was  per-
formed  using  Pearson’s  correlation  for  continuous  variables
with  a  normal  distribution  and  Spearman’s  rho correlation
for  continuous  variables  with  a non-normal  distribution.  Sta-
tistical  tests  and  corresponding  p-values  were  two-sided  and
a  p  value  <0.05  was  considered  statistically  significant.  IBM
SPSS  version  21.0  was  used for  all  statistical  analyses.
Results
Thirty-eight  patients  were  included  (mean  age  60.0±13.7
years,  29  male).  Mean  RHI was  1.87±0.60 and  16  patients
(42.1%)  had  ED  (RHI  <1.67).
The  main  characteristics  of  the  study  population  accord-
ing  to  the  presence  of  ED  are presented  in Table 1.  The
flowchart  of  the  patient  selection  process  and exams  per-
formed  in the study  is  presented  in  Figure  1.
There  were  no  significant  differences  between  the two
groups  in physical  characteristics,  risk  factors  or  previ-
ous  medication.  Admission  blood  tests  were also  similar
in  both  populations,  except  for high-sensitivity  C-reactive
protein,  which  showed  a  tendency  for  higher  values  in
patients  with  ED. There  were  no  significant  differences  in
ischemic  (pain-to-balloon)  time  between  patients  with  and
without  ED, although  there  was  a  trend  for  lower  door-
to-balloon  times  in  patients  with  ED.  The  prevalence  of
multivessel  disease  in  patients  with  ED  was  almost  twice
that  in patients  without  ED  (68.8%  vs.  36.4%),  although  this
difference  was  not  statistically  significant  (p=0.10).  SYN-
TAX  score  also  tended  to  be  higher  in patients  with  ED.
There  was  a clear  trend  towards  greater  area  at  risk,  mea-
sured  by  both  APPROACH  and  BARI  scores  (p=0.08  and  0.07,
respectively),  and these  two  scores  showed a  weak  but
significant  inverse  correlation  with  RHI  (r=-0.426,  p=0.008
and  r=-0.361,  p=0.026,  respectively).  RHI  values  tended  to
be  lower  in patients  in  whom  the  left anterior  descending
artery  (LAD)  was  the culprit  vessel  (1.74±0.65  vs.  2.02±0.51
in  other  vessels,  p=0.15).  Patients  with  ED  also  showed  a
trend  for  worse  initial TIMI  score  (TIMI  0-1:  93.8%  vs.  72.7%
in  patients  without  ED).  Finally,  treatment  options  (use of
mechanical  aspiration,  stent  implantation  technique  and
use  of  abciximab)  were  similar  in  patients  with  or  without
RHI  <1.67 (Table  1).
Extent  of infarction
Both  peak  TnI  and  the AUC  of  TnI  release  were  significan-
tly  higher  in  patients  with  ED  (Figure  2).  These  differences
were  even  more  significant  when TnI  values  were  indexed
to  the  area  at risk,  by both  the APPROACH  and BARI scores
(Table  2).
LVEF  by  echocardiography  was  significantly  lower  and
WMSI  significantly  higher  in patients  with  ED  (Figure  3).
Likewise,  GLS was  significantly  higher  in patients  with  RHI
<1.67,  although  there  were  no other  significant  differences
in  Doppler  variables  (Table  3).
On  ceCMR,  patients  with  ED  had  significantly  lower  LVEF
and  higher  WMSI,  confirming  the echocardiographic  results.
There  was  a  trend  for  more  transmural  necrosis  (22.2%  vs.
63.6%,  p=0.06)  and  greater  infarct  mass  (median  value  10.1%
vs.  17.5,  p=0.08)  in patients  with  RHI <1.67.  The  percentage
of  infarct mass  indexed  to  area-at-risk  scores  (APPROACH
and  BARI)  also  tended  to  be  higher  in patients  with  ED
(Table  4).
Microvascular  obstruction
ECG  resolution  of ST  elevation  was  numerically  less fre-
quent  immediately  after PCI  (median  60.5%  [IQR  72.0%]  vs.
76.5%  [IQR 41.0%]),  and  at 90  min  after reperfusion  (median
69.0%  [IQR 53.0%]  vs.  78.5  [IQR 28.0])  in patients  with  ED,
although  these  differences  were  not  statistically  significant
(p=0.23  and  0.07,  respectively).  However,  residual  total  ST
elevation  was  significantly  higher  on  both  ECGs  performed
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Table  1  Baseline  characteristics  of  the  study  population  according  to  the  presence  of  endothelial  dysfunction.
Variable  Total  population  (n=38)  Endothelial  dysfunction  (RHI  <1.67)  pd
No  (n=22) Yes  (n=16)
Physical  characteristics
Age  (years)a 60.0±13.7  60.1±12.4  59.8±15.7  0.94
Male genderb 29  (76.3)  18  (81.8)  11  (68.8)  0.58e
BMIa 27.2±4.0  27.4±4.5  27.1±3.3  0.82
Waist circumferencea 100.0±11.5  101.1±12.6  98.5±9.9  0.55
Risk factors  and  previous  coronary  diseaseb
Hypertension  26  (68.4) 16  (72.7) 10  (62.5) 0.50
Diabetes 12  (31.6) 8  (36.4) 4  (25.0) 0.46
Dyslipidemia  19  (50.0) 11  (50.0) 8  (50.0) 1.00
Active smoking  13  (34.2)  9 (40.9)  4 (25.0)  0.31
Previous angina  7  (18.4)  6 (27.3)  1 (6.3)  0.22e
Previous  revascularization  2  (5.3)  1 (4.5)  1 (6.3)  0.61e
Previous  medicationb
Aspirin/clopidogrel  3  (7.9) 2  (9.1) 1  (6.3) 0.73e
ACEIs/ARBs  13  (34.2) 10  (45.5) 3  (18.8)  0.11
Beta-blockers  1  (2.6) 1  (4.5) 0  (0.0) 0.85e
Statins  4  (10.5) 2  (9.1) 2  (12.5) 0.89e
Admission  laboratory  values
Creatinine  (mg/dl)c 0.88  (0.32)  0.87  (0.54)  0.90  (0.19)  0.67
NT-pro-BNP (pg/ml)c 158.5  (305.0)  154  (365)  163  (250)  0.95
hs-CRP (mg(dl)c 0.57  (0.71)  0.29  (0.45)  0.81  (0.98)  0.06
Blood glucose  (mg/dl)c 136.0  (63.0)  131.0  (60.0)  145.5  (81.8)  0.51
HbA1c (%)c 5.8  (1.3)  5.7 (1.4)  5.9  (2.1)  0.69
Ischemic times
Pain-to-balloon  time  (min)c 209 (173)  209  (186)  211  (167)  0.94
Door-to-balloon  time  (min)c 75  (52)  79  (46)  57  (44)  0.06
Angiographic  characteristics
Culprit  arteryb
Left  anterior  descending 21  (53.3)  11  (50.0)  10  (62.5)  0.89e
Left  circumflex  7  (18.4)  5 (22.7)  2 (12.5)
Right coronary 10  (26.3)  6 (27.3)  4 (25.0)
Multivessel  diseaseb 19  (50.0) 8  (36.4)  11  (68.8)  0.10e
SYNTAX  scorec 17.8±6.2  16.8±6.2  19.0±6.0  0.29
Initial TIMI  flow  0-1b 31  (81.6)  16  (72.7)  15  (93.8)  0.22
Area-at-risk scoresc
APPROACH  score  27.8  (3.0)  28.1  (5.0)  29.7  (10.0)  0.08
BARI score  28.5  (6.0)  26.7  (7.0)  30.2  (10.0)  0.07
Angioplasty variablesb
Mechanical  aspiration  16  (42.1)  9 (40.9)  7 (43.8)  0.86
Balloon pre-dilatation  21  (55.3)  13  (59.1)  8 (50.0)  0.58
Stent implantation  36  (94.7)  20  (90.9)  16  (100.0)  0.61
Balloon post-dilatation  24  (63.2)  14  (63.6)  10  (62.5)  0.94
Use of  abciximab  9  (23.7)  4 (18.2)  5 (31.5)  0.58
Mechanical aspiration  16  (42.1)  9 ((40.9)  7 ((43.8))  0.86
ACEIs: angiotensin-converting enzyme inhibitors; APPROACH: modified Alberta Provincial Project for Outcome Assessment in Coronary
Heart Disease; ARBs: angiotensin receptor blockers; BARI: Bypass Angioplasty Revascularization Investigation; BMI: body mass index;
HbA1c: glycated hemoglobin; hs-CRP: high-sensitivity C-reactive protein; NT-pro-BNP: N-terminal B-type natriuretic peptide.
a Mean ± standard deviation.
b Number (%).
c Median (interquartile range).
d Independent t test  for continuous variables with a  normal distribution, Mann-Whitney test for continuous variables with a non-normal
distribution, chi-square test for categorical variables.
e Yates’ correction.
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38 patients included in the cath lab
12 patients underwent echo study but the images were either unavailable (DICOM error)
or of inadequate quality for analysis
5 patients underwent echo study but the images were of inadequate
quality for analysis
4 patients refused ceCMR, mainly because of claustrophobia
3 patients did not undergo the exam due to logistical difficulties
1 patient underwent the exam but the images were lost
1 patient underwent the exam but the images were of inadequate quality for
analysis
38 patients with PAT data at 24 h
38 patients included in ECG analysis
26 patients with echo data
38 patients included in troponin I analysis
29 patients with ceCMR data
21 patients included in speckle tracking imaging analysis
Figure  1  Flowchart  of  the  patient  selection  process  and  exams  performed.  cath  lab:  catheterization  laboratory;  ceCMR:  contrast-
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Figure  2  Peak  troponin  I  and  area  under  the curve  of  troponin  I release  (determined  from  seven  scheduled  blood  tests  in the  first
48 h  after  P-PCI),  according  to  the presence  of endothelial  dysfunction.  RHI:  reactive  hyperemia  index.
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Table  2  Troponin  I release  according  to  the  presence  of  endothelial  dysfunction.
Variablea,b Total  population  (n=38)  Endothelial  dysfunction  (RHI  <1.67)  pc
No  (n=22)  Yes  (n=16)
TnI  (ng/dl)
Peak  TnI  95  (96)  67  (81)  118  (186)  0.024
Peak TnI  (APPROACH)  25  (32)  17  (20)  34  (56)  0.009
Peak TnI  (BARI)  24  (31)  17  (22)  33  (47)  0.008
Peak TnI  (both  scores)  24  (31)  17  (21)  33  (55)  0.009
AUC
AUC of  TnI  release 1293  (1580) 1076  (1042) 2305  (2486) 0.012
AUC of  TnI  release  (APPROACH) 403  (522) 315  (303) 664  (1080) 0.008
AUC of  TnI  release  (BARI) 383  (448) 314  (326) 618  (799) 0.007
AUC of  TnI  release  (both  scores)  393  (482)  314  (300)  641  (984)  0.007
APPROACH: modified Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease; AUC: area under the curve; BARI:
Bypass Angioplasty Revascularization Investigation; TnI: troponin I.
a Median (IQR).
b Peak value and area under the  curve (AUC) of seven serial troponin I  measurements performed in the first 48 h after primary

































Wall motion score index
Figure  3  Left  ventricular  ejection  fraction  (mean  ±  standard  deviation)  and  wall  motion  score  index  (median  and  interquartile
range) assessed  by  echocardiography,  according  to  the  presence  of  endothelial  dysfunction,  defined  as  RHI  <1.67.  *independent  t
test; **Mann-Whitney  test;  RHI:  reactive  hyperemia  index.
immediately  after  PCI  (median  5.0  mV  [IQR 12.0  mV] vs.
2.5  mV  [IQR  5.09  mV],  p=0.048)  and  at  90  min  (median  3.0
mV  [IQR  7.0  mV]  vs.  1.3  mV  [IQR  4.0  mV])  in patients  with
RHI  <1.67.
All  angiographic  measures  of  microvascular  dysfunction
after  STEMI  showed  important  trends  towards  worse  results
in  patients  with  RHI  <1.67:  cTFC was  higher  (19.5  [IQR 12.0]
vs.  16.4  [IQR  7.0],  p=0.07)  and TMPG  2 or  3 was  less  frequent
(56.3%  vs.  86.4%,  p=0.09).  Likewise,  there  was  a  clear  trend
toward  higher  values  of  IMR  in patients  with  ED:  median  40.5
(IQR  54.4)  vs.  22.0  (IQR  26.0) (p=0.09).  The  prevalence  of
microvascular  coronary  damage,  defined  as  median  IMR  >24,
was  almost  two  times  higher  in  patients  with  ED  (62.5%  vs.
36.4%,  p=0.11).
ceCMR  showed  a significant  higher  proportion  of  patients
with  MVO  when  ED  was  present  (54.5%  vs.  11.1%,  p=0.03).
MVO  mass  was higher  in the group  with  RHI  <1.67 (median
6.8  vs. 5.3),  although  the  difference  was  not  statistically
significant.
Discussion
To  our  knowledge,  this  is the first  study  reporting  the relation
between  peripheral  ED measured  early  (24 h)  and  microvas-
cular  coronary  damage  and myocardial  infarction  extension
in patients  with  STEMI  treated  with  P-PCI.
The  presence  of  ED in  patients  with  ACS  has  been
repeatedly  demonstrated.  Elbaz  et al.  invasively  assessed
endothelial  function  in non-culprit  arteries  in patients
with  non-ST  elevation  acute  coronary  syndrome  (NSTE-
ACS)  using  intracoronary  acetylcholine  infusion  and found
that  81%  of patients  had a blunted  response  to this
endothelium-dependent  vasodilator.40 Spiro  et  al. used
flow-mediated  dilation  and  low  flow-mediated  constriction
to  demonstrate  that  endothelial  function  is  significantly
more  compromised  in patients  with  NSTE-ACS  compared
to  patients  with  stable  CAD,  both  before  and  after
angioplasty.41 Careri  et al. assessed  endothelial  function
in  the  first  12  h in both  stable  and  NSTE-ACS  patients,
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Table  3  Echocardiographic  results  according  to  the  presence  of  endothelial  dysfunction.
Variable  Total  population  Endothelial  dysfunction  (RHI  <1.67)  pc
No Yes
2D  measurements  (n=26)  (n=15)  (n=11)
LVEDV (ml)a 109.8±23.4  106.5±30.2  113.8±11.4  0.48
LVESV (ml)a 55.9±12.6  51.1±12.3  61.7±10.9  0.047
LVEF (%)a 48.6±7.1  51.4±4.7  45.3±8.3  0.045
WMSIb 1.44  (0.41)  1.35  (0.47)  1.77  (0.47)  0.006
LA volume  (ml/m2)a 36.1±11.0 36.7±12.1 35.3±10.0 0.78
Doppler  measurements (n=21)  (n=11)  (n=10)
E/A ratioa 1.10±0.40 1.17±0.40 0.97±0.0.39 0.30
E/e′ ratioa 8.91±3.30 8.83±3.91 9.05±2.18 0.89
2D  speckle  tracking  (n=21)  (n=11)  (n=10)
GLSa -13.16±2.35  -14.32±1.72  -11.89±2.35  0.014
2D: two-dimensional; GLS: global longitudinal strain; LA: left atrial; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular
ejection fraction; LVESV: left ventricular end-systolic volume; WMSI: wall motion score index.
a Mean ± standard deviation.
b Median (interquartile range).
c Independent t test for continuous variables with a normal distribution, Mann-Whitney test for continuous variables with a non-normal
distribution.
Table  4  Contrast-enhanced  cardiac  magnetic  resonance  results  according  to  the  presence  of  endothelial  dysfunction.
Variable  Total  population  (n=29)  Endothelial  dysfunction  (RHI  <1.67)  pd
No  (n=18)  Yes  (n=11)
LVEDV  (ml)a 138.6±26.9  139.2±26.5  137.5±28.9  0.87
LVESV (ml)a 63.5±21.0  59.3±19.4  70.4±22.6  0.17
LVEF (%)a 53.9±8.4  56.6±8.1  49.5±7.2  0.025
WMSIa 1.37±0.33  1.28±0.31  1.53±0.32  0.05
Edema massb 19.1  (19.0)  17.2  (14.1)  21.2  (28.6)  0.28
Transmural necrosisc 12  (38.7)  4  (22.2)  7 (63.6)  0.06e
Infarct  mass
Totalb 11.6  (9.3)  10.1  (10.3)  17.5  (15.4)  0.08
Percentageb 11.5  (13.7)  10.2  (7.6)  17.5  (21.8)  0.10
Indexed to  APPROACH 3.2  (7.0)  2.7  (2.6)  4.9  (11.5)  0.10
Indexed to  BARI 3.4  (5.8) 2.3  (2.7)  5.1  (11.5)  0.09
Salvaged massb 5.0  (14.0)  5.0  (8.8)  4.7  (27.6)  0.87
MVO
Presentc 8  (27.6)  2  (11.1)  6 (54.5)  0.03e
Massb 6.1  (15.5)  5.3  (-)  6.8  (20.8)  0.29
APPROACH: modified Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease; BARI: Bypass Angioplasty Revascu-
larization Investigation; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular
end-systolic volume; MVO: microvascular obstruction; WMSI: wall motion score index.
a Mean ± standard deviation.
b Median (interquartile range).
c Number (%).
d Independent t test for continuous variables with a normal distribution, Mann-Whitney test for continuous variables with a non-normal
distribution, chi-square test for categorical variables.
e Yates’ correction.
and  showed  that  flow-mediated  dilation  is  significantly
lower  in  acute  patients.20 Finally,  we  also  demonstrated
that  patients  with  STEMI  treated  with  P-PCI  have a high
prevalence  of  ED as  assessed  with  PAT  3-5  days  after  the
event.21
Importantly,  peripheral  endothelial  function  has  been
shown  to  relate  closely  with  coronary  microvascular  dys-
function,  using several  different  techniques42--44 including
PAT.45 However,  the  exact  role of peripheral  ED  (as a  sur-
rogate  for  coronary  ED)  in the early  phase  after  P-PCI
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has  never  been  investigated.  Testing  peripheral  endothe-
lial  function  is particularly  challenging  in acute  patients,
for  several  reasons:  in addition  to  the  unpredictable  nature
of the  acute  event  onset,  patients’  unstable  condition  and
the  pain,  anxiety  and fear  they  usually  experience,  it is
generally  impossible  to  comply  with  several  recommenda-
tions  for  endothelial  function  assessment,  including  fasting
state,  morning  exam,  avoidance  of  caffeine  or  smoking,
etc.46 Additionally,  our  patients  were  assessed  after  an arte-
rial  puncture  (for  urgent  angiography)  and  several  venous
punctures  (both  for  blood  tests  and  for  administration  of
drugs).  Finally,  the time  of  day was  not  the  same  for  all
measurements  (since  it depended  on  the time  of  the pri-
mary  angioplasty),  and  therefore  patients  may  or  may  not
have  been  in a  fasting  state.
Notwithstanding  all  these  potential  pitfalls,  the  RHI
results  we  describe  in  this  population  are similar  to  the
values  reported  by  Schoenenberger  et  al. (1.82±0.48)  in
the  only  published  study  that also  measured  RHI  24  h  after
P-PCI  in  STEMI  patients.23 Furthermore,  the  percentage  of
patients  with  RHI <1.67  (42.1%)  is  consistent  with  the results
observed  in  all  studies  that  reported  this information  in the
acute/subacute  phase  of ACS:  47.9%  in the  study  by  Yamo-
moto  et  al.,25 43.1%  in our  pilot  study21 and  45.0%  in the
study  by  Schoenenberger  et al.23
Patients  with  RHI  <1.67  had  significantly  higher  values  of
both  peak  TnI and  AUC  of TnI  release,  both  total  and  indexed
to  the  area-at-risk  scores.  Correspondingly,  they  had a  three-
fold  higher  risk  of  transmural  necrosis  and  a  clear  trend
to  higher  total  and  percentage  infarct  mass on  ceCMR.  In
line  with  these  results,  they  also  had  lower  LVEF and  higher
(worse)  WMSI,  both  on the  initial  echocardiogram  and  on
ceCMR.
Similarly,  patients  with  RHI  <1.67  had  a  clear  trend
towards  worse  electrocardiographic  (particularly  residual
ST  elevation  after  P-PCI)  and  angiographic  (IMR,  cTFC
and  TMPG)  indicators  of microvascular  reperfusion.  Alto-
gether,  these  data  suggest greater  damage  to  the coronary
microvasculature  in patients  with  peripheral  ED,  which  is
confirmed  by  the  ceCMR  results:  patients  with  RHI <1.67
were  almost  five  times  more  likely  to  have  MVO  on  ceCMR,
and  tended  to  have  greater  MVO  mass.
The  fact  that  patients  with  ED  tended  to  have more
severe  CAD (the  prevalence  of  multivessel  disease was
almost  twice  as  high  in patients  with  ED,  and SYNTAX  scores
also  tended  to  be  higher  in these  patients)  is  in agree-
ment  with  our  previous  work24 and  suggests  that  at least
the  previous  severity  of CAD  is  related  to  ED.  We  also
found  a  trend  for  lower  initial TIMI  flow  in patients  with
ED,  which  is  in agreement  with  a recent  study  by  Kandhai-
Ragunat  et  al.  These  authors  documented  lower  RHI values
(although  measured  4-6 weeks  after  STEMI)  in  patients  with
an  occluded  artery  before  P-PCI,  compared  with  patients
with  a  patent  artery (2.08±0.34  vs.  1.75±0.35;  p<0.007),26
suggesting  that ED  may  be  involved  in microvascular  reper-
fusion  in STEMI  patients.
However,  we  also  found a significant  negative  correla-
tion  between  both area-at-risk  scores  and  RHI,  and there
was  a  trend  for  lower  RHI in patients  in whom  the  LAD  was
the  culprit  artery.  Both larger  areas  at risk  and  the LAD as
culprit  artery  are  associated  with  larger  infarctions,  imply-
ing that  the  documented  lower  RHI  values  may  reflect  the
extension  of  the  infarction,  as  opposed  to  being  part  of  the
pathophysiological  process  that  caused  it.  Indeed,  our find-
ing  that  patients  with  ED  in  the first  24  h  after STEMI  have
larger  infarcts  and  lower  LVEF  is  in  line  with  the  evidence
of  neurohumoral  activation  in  patients  with  heart  failure.
It has been  demonstrated  that  reduction  in stroke  vol-
ume  produces  lower  endothelial  shear  stress,  which  causes
dysregulation  in gene  expression  of  nitric  oxide  (NO)  syn-
thase  isoforms,47,48 leading  to  reduced  NO  bioavailability.49
Furthermore,  there  is  an additional  reduction  in NO  bioavail-
ability  caused  by  direct  destruction  of  NO  by  reactive  oxygen
species,  mainly  driven  by  an increase  in angiotensin  II  and
aldosterone  activity,  and purine  metabolism.50
While  we  cannot  infer  from  our  results  whether  ED was  a
cause  or  a  consequence  of  the  severity  of  myocardial  infarc-
tion,  it is reasonable  to conclude  that  peripheral  ED  in  these
patients  may  be a  marker  of  the severity  of  myocardial
disease  and therefore  of  its systemic  consequences,  which
makes  it  useful  to assess  the  effectiveness  of  therapy  and to
predict  events,  independently  of  its  exact  pathophysiologi-
cal  role.
In patients  with  acute  myocardial  infarction,  early  treat-
ment  with  statins,  which  are known  to  reduce  events,
was  initially  assessed  through  their  beneficial  effect  on
endothelial  function.51,52 Likewise,  in heart  failure  patients,
peripheral  endothelial  function has  been  described  as  a
tool  to  predict  response  to  cardiac  resynchronization  ther-
apy (CRT),  and ED  improvement  after  CRT correlates  with
functional  improvement,53 related  to  an increase  in cardiac
output,54 likely  mediated  by  shear stress.55
In summary,  although  it is  not  possible  at this point to
determine  the exact  role  of  ED  in STEMI  patients,  we  demon-
strate  that  its  measurement  early  after  P-PCI  is  feasible  and
related  to  infarct  extent  and  MVO,  which makes  it a  valu-
able  tool  for identifying  high-risk  patients  and  for  testing
new  pharmacological  or  device-based  strategies.
Study limitations
This  study  is  limited  by  the  small  study  sample,  and larger
studies  will  be necessary  to  confirm  these results.  Addition-
ally,  the  EndoPAT  exams  were  not performed  in  accordance
with  recommendations  for  assessing  endothelial  function:
patients  were  not  fasting,  coffee  or  tea  consumption  was
not excluded  and  the  exam  was  not  necessarily  performed
in the morning.  However,  measuring  endothelial  function  in
the  acute  phase  was  in fact the purpose  of the study.  Impor-
tantly,  all  the operators  performing  the  EndoPAT  assessment
were  highly  trained  in this  procedure,  having  participated  in
several  previous  studies.
Conclusions
The  presence  of  ED assessed  by  PAT at 24  h after  P-PCI  in
patients  with  STEMI  is  associated  with  larger  infarcts,  lower
LVEF,  higher  WMSI  and  higher  prevalence  of  MVO.
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